Abstract: Disclosed is an anti-adhesion agent composition which uses a high molecular weight compound having biocompatibility and an oil derived from animals, plants, and minerals so as to improve low viscosity and low strength, which are problems of existing anti-adhesion agents, and prevent adhesion between living tissues. The anti-adhesion composition according to the present disclosure performs a physical barrier function through simple mixing of a polymer material, serving as a physical barrier in its anti-adhesion effect, and a solvent, and remains in the body for a certain period of time, then decomposes, absorbs, and is excreted. The anti-adhesion composition does not interfere with the healing of the wound after surgery, and exhibits an excellent effect of convenient application to the surgical site.

Abstract: A display device includes a display panel including pixels in one pixel column and a gate driver for sequentially providing scan signals to the pixels. Each of the pixels includes a light emitting element, a first transistor for controlling a current amount of driving current flowing through the light emitting element and a second transistor for transferring a data signal to a gate electrode of the first transistor in response to a corresponding scan signal among the scan signals. A first pixel among the pixels is electrically connected to a first data line, and a second pixel adjacent to the first pixel among the pixels is electrically connected to a second data line different from the first data line. A second scan signal provided to the second pixel partially overlaps with a first scan signal provided to the first pixel.

Abstract: A semiconductor device includes a gate stack structure including insulating patterns and conductive patterns which are alternately stacked, a first separation structure penetrating the gate stack structure, a second separation structure penetrating the gate stack structure and being adjacent to the first separation structure, first and second memory channel structures penetrating the gate stack structure and disposed between the first separation structure and the second separation structure, a first bit line overlapping with the first and second memory channel structures and electrically connected to the first memory channel structure, and a second bit line overlapping with the first and second memory channel structures and the first bit line and electrically connected to the second memory channel structure.

Abstract: A semiconductor memory device includes a gate stack structure including insulating layers, a lower selection line and word lines, the word lines including a first word line adjacent to the lower selection line and a second word line on the first word line, a memory channel structure penetrating the gate stack structure, a plurality of first contact plugs electrically connected to the first word line, a plurality of second contact plugs electrically connected to the second word line, a first conductive line connected to the plurality of first contact plugs, and a second conductive line connected to one of the plurality of second contact plugs.

Abstract: The present invention relates to a multilayer suppository formulation comprising an outer layer containing a first pharmaceutical ingredient and an inner layer containing a second pharmaceutical ingredient, and a composition comprising the same for prevention or treatment of colorectal cancer. The present invention reproduces the release order and release interval of composite drugs administered sequentially in combination, for example, FOLFOX, in the same manner. Accordingly, the present invention can be used as an effective dosage form that concentrates a pharmacological effect, reduces a side effect, and greatly improves dosing convenience for a patient by locally administering combined drugs which had been co-administered systemically through intravenous injection, in a lesion-specific manner.

Abstract: The present invention relates to a donepezil eutectic mixture and a use thereof. A eutectic mixture of the present invention allows increased solubility and skin permeability of donepezil, and a pharmaceutical composition including the same does not generate donepezil crystals and maintains amorphous form even when stored under various conditions, thereby being applicable to various formulations while also having excellent stability and efficacy.

Abstract: A bilayer combination tablet for oral administration, which is prescribed for alleviation of symptoms or signs of osteoarthritis (degenerative arthritis), alleviation of symptoms or sings of rheumatoid arthritis, alleviation of symptoms or signs of ankylosing spondylitis, alleviation of acute pain in adults (post-operative or post-tooth extraction pain), alleviation of primary dysmenorrhea, or alleviation of severe and moderate acute or chronic pain. The bilayer combination tablet includes: a controlled-release layer containing tramadol as an active ingredient; and an immediate-release layer containing celecoxib as an active ingredient. A composition for treating pain may be provided, which has a long-lasting analgesic effect for 12 hours while reducing the side effects of tramadol by slow release of water-soluble tramadol and immediate release of poorly soluble celecoxib.

Abstract: Organic light-emitting display devices are provided. One organic light-emitting display device includes a substrate, a first wire on the substrate, a second wire insulated from and crossing the first wire, and a static electricity dispersion pattern insulated from and crossing the second wire. Another organic light-emitting display device includes: a substrate; a gate line and a data line on the substrate, insulated from and crossing each other; a dummy wire that is part of a same layer as one of the gate line or the data line, and having at least one end aligned with a sidewall of the substrate; a dummy intersection wire insulated from and crossing the dummy wire; and a static electricity dispersion pattern insulated from and crossing the dummy intersection wire.

Abstract: The present invention provides a pharmaceutical composition including an ionic liquid composed of a triptan compound and saccharin. Since a triptan compound and saccharin form an ionic liquid to increase the solubility of the triptan compound in the present invention, it is possible to expect a rapid and high dissolution of the triptan compound when a pharmaceutical composition is prepared. In addition, large amounts of organic solvents and acidic solvents need not be used in order to dissolve the triptan compound.

Abstract: Disclosed is a method for preparing a liposome formulation. In the disclosed method, a lipid fraction is dissolved in an organic solvent. The solution including a bioactive component and the lipid fraction, together with a carrier, is put in a reaction vessel, and a supercritical fluid is introduced thereto, so as to prepare particles coated with the bioactive component-lipid. The supercritical fluid is discharged by compression to obtain proliposome particles, and then the proliposome particles are hydrated by an aqueous solution including water so as to form a liposome solution. Preferably, the formulation may include one or more bioactive components. As required, the liposome formulation may be further processed by methods such as particle size reduction, removal of organic solvent, and freeze-drying. The preparation method can be easily carried out at a laboratory scale. Furthermore, the same method can be employed in liposome formulation preparation in mass production, or at a commercial scale.

Abstract: The present invention provides a pharmaceutical composition including an ionic liquid composed of a triptan compound and saccharin. Since a triptan compound and saccharin form an ionic liquid to increase the solubility of the triptan compound in the present invention, it is possible to expect a rapid and high dissolution of the triptan compound when a pharmaceutical composition is prepared. In addition, large amounts of organic solvents and acidic solvents need not be used in order to dissolve the triptan compound.

Abstract: The present invention provides a pharmaceutical formulation for increasing the dissolution rate of a lipase inhibitor and reducing side effects of the lipase inhibitor, including oily anal leakage, and a method for preparing the same, the pharmaceutical formulation comprising: a lipase inhibitor, and a porous adsorbent on which a thin film of the lipase inhibitor is formed.

Abstract: An organic light emitting display apparatus includes a polarizer film arranged on a substrate or an encapsulation substrate that faces an image realized by a display unit, wherein the polarizer film includes a plurality of regions having different light transmittances. By using the polarizer film, a luminance difference due to a voltage drop may be compensated for so that a uniform luminance may be obtained when the image is realized.

Abstract: An organic light-emitting display apparatus with improved electric properties comprises: a substrate; an insulation layer which is formed on the substrate, and which includes a penetration hole; a first electrode which is formed on the insulation layer; an intermediate layer which is formed on the first electrode, and which includes an organic light-emitting layer; a second electrode which is formed on the intermediate layer; and a fixing member which is formed in the penetration hole, and which contacts the first electrode.

Abstract: A flat panel display integrated with a touch screen panel. The connecting patterns, which connect adjacent first sensing cells and adjacent second sensing cells are formed on the same level of the lower surface of the upper substrate of the flat panel display of the same material as metal patterns formed around the edge of the touch screen panel, and by arranging the connecting patterns not to cross each other. The flat panel display panel can also be integrated with a touch screen having improved visibility by forming the touch screen panel on the upper substrate of the flat panel display such that connecting patterns are formed in the regions between the pixels.

Abstract: An organic light-emitting display apparatus including first and second edge sub-pixel lines disposed at opposing side edges of the apparatus and center sub-pixel lines disposed therebetween, each for emitting a single color of light. An external emission width of the first edge sub-pixel line is less than an external emission width of the center sub-pixel lines that emit the same color. An external emission width of the second edge sub-pixel line is less than the width of the center sub-pixel lines that emit the same color.

Abstract: The present invention relates to a novel technology for forming fine particles with a size of 0.0˜23 microns from a solid that can be dissolved in a liquid solvent and is not decomposed by heat. The particle preparation technology according to the present invention may be applicable to the fields of food, cosmetics, biopolymer, polymer compositions, and pharmaceuticals.

Abstract: Organic light-emitting display devices are provided. One organic light-emitting display device includes a substrate, a first wire on the substrate, a second wire insulated from and crossing the first wire, and a static electricity dispersion pattern insulated from and crossing the second wire. Another organic light-emitting display device includes: a substrate; a gate line and a data line on the substrate, insulated from and crossing each other; a dummy wire that is part of a same layer as one of the gate line or the data line, and having at least one end aligned with a sidewall of the substrate; a dummy intersection wire insulated from and crossing the dummy wire; and a static electricity dispersion pattern insulated from and crossing the dummy intersection wire.

Abstract: Disclosed is a method for preparing a liposome formulation. In the disclosed method, a lipid fraction is dissolved in an organic solvent. The solution including a bioactive component and the lipid fraction, together with a carrier, is put in a reaction vessel, and a supercritical fluid is introduced thereto, so as to prepare particles coated with the bioactive component-lipid. The supercritical fluid is discharged by compression to obtain proliposome particles, and then the proliposome particles are hydrated by an aqueous solution including water so as to form a liposome solution. Preferably, the formulation may include one or more bioactive components. As required, the liposome formulation may be further processed by methods such as particle size reduction, removal of organic solvent, and freeze-drying. The preparation method can be easily carried out at a laboratory scale. Furthermore, the same method can be employed in liposome formulation preparation in mass production, or at a commercial scale.

Abstract: An organic light emitting device is disclosed. In one embodiment, the device includes a plurality of pixels formed on a substrate, wherein each of the pixels includes: a first electrode layer formed on the substrate; an organic emission layer formed on the first electrode layer and a second electrode layer formed on the organic emission layer. Further, at least one of the first electrode layers of the pixels is externally patterned.